In BRAFi resistant tumours and cell lines, we confirm AR upregulation predominantly in the MITF<sup>low</sup>/AXL<sup>high</sup> undifferentiated/neural-crest like state, but it also occurs in the MITF<sup>high</sup>/AXL<sup>low</sup> differentiated melanocytic state. This evidence concerns the gene MITF and neoplasm.